Future Health Lab
Alfred-Adler-Straße 1, Vienna, Austria
Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used for the diagnosis (i.e., staging and restaging) and treatment of patients with prostate cancer. Radionuclide PSMA therapy is a useful new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and potentially also in patients with hormone-sensitive prostate cancer. The course will cover the spectrum of […]
Radionuclide Theranostics is evolving and expanding in the field of nuclear medicine in various clinical settings. Its principle is based on therapeutic interventions after imaging to confirm the presence of a biological target. However, there are several clinical and technical challenges in setting up a successful theranostics team and facility. The common challenges include logistics, […]
While PET imaging with radionuclides such as F18 and Ga68 have proven to provide high quality diagnostic imaging, imaging with other radionuclides can be more challenging. Zr-89 is one such radionuclide. Although Zr-89 has advantageous labelling properties for cell imaging and the imaging of monoclonal antibodies, the radionuclide is non-ideal imaging qualities mostly due to […]
